Baseline participant characteristics, study treatments, and responses
| Participant . | Age, y . | Sex . | Race/ethnicity . | HIV VL copies per mL . | CD4+ T cells per μL . | Pathology . | ECOG . | MMSE . | Response after induction . | Second-line therapy . | Long-term outcome . | ΔCD4+ T cells per μL . | ΔMMSE . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 21 | M | Af Am | 8570* | 13 | EBV+ DLBCL, non-GCB† | 2 | 28 | PR | — | Death | +35 | — |
| 2 | 45 | M | African | <50* | 409 | DLBCL, GCB† | 2 | 21 | PR | Ara-C + MTX | CR | +10 | +7 |
| 3 | 34 | F | Af Am | <50 | 0 | EBV+ BCL, polymorphic | 2 | 20 | NA | — | Death | 0 | — |
| 4 | 39 | M | Af Am | 243 000 | 80 | EBV+ BCL (CSF only)† | 2 | 5 | PR | R + TMZ | CR | +369 | +23 |
| 5 | 36 | F | Af Am | 77 650 | 1 | EBV+ DLBCL, non-GCB | 3 | ND | CR‡ | — | CR | +30 | — |
| 6 | 31 | M | Hispanic | <50* | 165 | EBV+ BCL, polymorphic | 1 | 29 | CR | — | CR | +35 | −1 |
| 7 | 31 | M | Hispanic | 102 000 | 43 | EBV+ BCL, polymorphic† | 1 | 18 | CR | — | CR | +177 | +12 |
| 8 | 23 | F | White | 99 300 | 2 | EBV+ DLBCL, NOS | 2 | 27 | CR | — | CR | +56 | +3 |
| 9 | 55 | M | Af Am | 314* | 78 | EBV+ BCL, polymorphic | 3 | 16 | CR | — | CR | −54 | +11 |
| 10 | 22 | M | Af Am | 145 600 | 0 | EBV+ DLBCL, non-GCB | 3 | 29 | PR | R + TMZ | CR | +14 | 0 |
| 11 | 26 | M | Af Am | 1 934 000 | 8 | EBV+ DLBCL, non-GCB | 3 | 28 | PD | R + TMZ + WBRT | Death | +41 | — |
| 12 | 38 | M | Af Am | 191 900 | 19 | EBV+ BCL, polymorphic | 3 | ND | NA | — | Death | — | — |
| Participant . | Age, y . | Sex . | Race/ethnicity . | HIV VL copies per mL . | CD4+ T cells per μL . | Pathology . | ECOG . | MMSE . | Response after induction . | Second-line therapy . | Long-term outcome . | ΔCD4+ T cells per μL . | ΔMMSE . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 21 | M | Af Am | 8570* | 13 | EBV+ DLBCL, non-GCB† | 2 | 28 | PR | — | Death | +35 | — |
| 2 | 45 | M | African | <50* | 409 | DLBCL, GCB† | 2 | 21 | PR | Ara-C + MTX | CR | +10 | +7 |
| 3 | 34 | F | Af Am | <50 | 0 | EBV+ BCL, polymorphic | 2 | 20 | NA | — | Death | 0 | — |
| 4 | 39 | M | Af Am | 243 000 | 80 | EBV+ BCL (CSF only)† | 2 | 5 | PR | R + TMZ | CR | +369 | +23 |
| 5 | 36 | F | Af Am | 77 650 | 1 | EBV+ DLBCL, non-GCB | 3 | ND | CR‡ | — | CR | +30 | — |
| 6 | 31 | M | Hispanic | <50* | 165 | EBV+ BCL, polymorphic | 1 | 29 | CR | — | CR | +35 | −1 |
| 7 | 31 | M | Hispanic | 102 000 | 43 | EBV+ BCL, polymorphic† | 1 | 18 | CR | — | CR | +177 | +12 |
| 8 | 23 | F | White | 99 300 | 2 | EBV+ DLBCL, NOS | 2 | 27 | CR | — | CR | +56 | +3 |
| 9 | 55 | M | Af Am | 314* | 78 | EBV+ BCL, polymorphic | 3 | 16 | CR | — | CR | −54 | +11 |
| 10 | 22 | M | Af Am | 145 600 | 0 | EBV+ DLBCL, non-GCB | 3 | 29 | PR | R + TMZ | CR | +14 | 0 |
| 11 | 26 | M | Af Am | 1 934 000 | 8 | EBV+ DLBCL, non-GCB | 3 | 28 | PD | R + TMZ + WBRT | Death | +41 | — |
| 12 | 38 | M | Af Am | 191 900 | 19 | EBV+ BCL, polymorphic | 3 | ND | NA | — | Death | — | — |
Af Am, African American; Ara-c, cytarabine; BCL, B-cell lymphoma; ECOG, Eastern Cooperative Oncology Group; DLBCL, diffuse large B-cell lymphoma; GCB, germinal center B-cell; NA, not applicable (patient did not complete induction therapy); ND, not done; NOS, not otherwise specified; PR, partial response; R, rituximab; SCL, small-cell lymphoma; TMZ, temozolomide; VL, viral load; WBRT, whole-brain radiotherapy.
Indicates participants receiving ART before diagnosis of PCNSL.
Indicates leptomeningeal involvement of PCNSL confirmed by flow cytometry.
Participant 5 was initially ineligible to receive HD-MTX because of renal dysfunction and received R with TMZ (150 mg/m2) for 5 days for 1 cycle followed by 6 cycles of R plus HD-MTX plus TMZ.